The irony is, J&J could have had this company for $76 a share.

The price that I think you'd have to pay for St. Jude would be even more expensive than what Guidant is being bid for today.

There's kind of an axiom out there that when Larry Best buys you should buy and when Larry Best sells you should sell.

They are pushing the envelope.

A combination of new product launches, contract selling, Guidant missteps, and a favorable market dynamic have increased St. Jude's overall worldwide market share.

Q4 is behind us, and what the Boston Scientific investment thesis is now is the future, and particularly the future with Guidant. I expect, if they allow us, that's going to be the focus of the conference call.